Pharma & Biotech - Page 9

Fujifilm Biotechnologies has announced a significant leadership transition, naming Maja Pedersen as President in addition to her existing role as Chief Operating Officer. The appointment takes effect immediately and marks a deliberate

ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), has launched a new multichannel campaign called “Do It For Future You” aimed at encouraging people to act on their

AstraZeneca (AZN) and CSPC Pharmaceutical Group have signed a joint venture contract to construct a new-generation biologics manufacturing facility in Shijiazhuang, China. The agreement marks the third strategic deal the two companies

Moderna has secured a landmark FDA approval for mFlusiva, its mRNA-based influenza vaccine, marking the first time mRNA technology has been cleared for flu prevention in the United States. The approval covers

Emergent BioSolutions has undergone a series of sweeping restructuring efforts, eliminating senior roles and consolidating operations as part of a broad turnaround strategy. Joseph Papa, just two months into his role as

Kenco, one of the United States’ leading third-party logistics providers, has rolled out AI agents across its enterprise operations in a move drawing significant industry attention. The company deployed DeepFabric AI agents

Eli Lilly’s second-quarter revenues surged to $23 billion, a 48% year-over-year increase that comfortably beat analyst consensus estimates of $20.6 billion. The result also represented a 16% sequential increase, a sharp acceleration

Reddit has quietly emerged as a leading destination for women seeking candid, anonymous health information, according to a new report from Reddit and Omnicom’s The Weber Shandwick Collective. The report, titled “The

Johnson & Johnson has announced the retirement of Jennifer Taubert, 62, worldwide chair of J&J Innovative Medicine, after more than 21 years with the company. Taubert joined J&J’s executive committee in 2018

Pfizer has announced an additional $2.5 billion in planned cost savings, extending its sweeping cutback programme through 2029 and bringing its total reduction target to $9.7 billion. The New York-based pharmaceutical giant